Virginia Commonwealth University

Organix, Inc.

Other

Temple University

Billy R Martin

Raj K Razdan

Anu Mahadevan

Mohamad I Damaj

Peter R Byron

Joanne Peart

Aron H Lichtman

George Kunos

David Baker

Martin W Adler

Ronald F Tuma

Roger G Pertwee

Ming Zhang

A method is provided for treating a patient in need of therapy for central nervous system inflammation comprising administering to that patient a therapeutically effective amount of a cannabinoid agonist having efficacy at the CBreceptor but having substantially no efficacy at the CBreceptor at that amount.

Inflammation therapy

Compounds of the formula: wherein R, R1 and R4 are defined in the specification, and pharmaceutically acceptable salts, esters and tautomers thereof, having activity at peripheral cannabinoid receptors, commonly designated the CB2 receptor class. The compounds are useful for therapy, especially in the treatment of pain, inflammation and autoimmune disease.

Cannabinoids

Cannabinoid agonists and antagonists are provided for use in the treatment of disorders such as acute and chronic pain, inflammation, loss of appetite, convulsions, multiple sclerosis, nausea and vomiting. The cannabinoid agonists and antagonists contain a sulfonamide moiety incorporated into the cannabinoid side chain, and the side chain itself may be saturated or unsaturated.

Sulfonamide cannabinoid agonists and antagonists

The invention compounds and methods for the treatment of motor disorders. In particular, the invention provides eicosanoid analogs which are effective in ameliorating motor disorders such as spasticity caused by multiple sclerosis (MS).

Anti-spasticity of an eicosanoid analog

The present invention provides therapeutic formulations for solutions of &Dgr; -tetrahydrocannabinol (&Dgr; THC) to be delivered by metered dose inhalers. The formulations, which use, non-CFC propellants, provide a stable aerosol-deliverable source of &Dgr; THC for the treatment of various medical conditions, such as: nausea and vomiting associated with chemotherapy-muscle spasticity; pain; anorexia associated with AIDS wasting syndrome, epilepsy; glaucoma; bronchial asthma; and mood disorders.

&Dgr;9 tetrahydrocannabinol (&Dgr;9 THC) solution metered dose inhalers and methods of use

Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes the cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotuctants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH , and COCH 

Vasodilator cannabinoid analogs

The present invention provides therapeutic formulations for solutions of &Dgr; -tetrahydrocannabinol (&Dgr; THC) to be delivered by metered dose inhalers. The formulations, which utilize non-CFC propellants, provide a stable aerosol-deliverable source of &Dgr; THC for the treatment of various medical conditions, such as: nausea and vomiting associated with chemotherapy; muscle spasticity; pain; anorexia associated with AIDS wasting syndrome; epilepsy; glaucoma; bronchial asthma; and mood disorders.

&Dgr;9 Tetrahydrocannabinol (&Dgr;9 THC) solution metered dose inhaler

Pyrazole cannabinoid agonist and antagonists

The present invention relates to treatment of pain with a new class of analgesic compounds. More particularly, the present invention relates to a method for reducing pain of a patient involving administering to a patient an effective amount of an aryl substituted olefinic amine compound. In one aspect, the inventive method of reducing pain in a patient involves use of metanicotine compounds as the analgesic agent.

Compounds and pharmaceutical compositions thereof for eliciting

Water-soluble esters of tetrahydrocannabinoids, which are well-suited for administration in therapeutic aqueous formulations, having following general formula: ##STR1## wherein a - - - b designates a 9(10) or a 9(8) double bond, R' is a --(CH.sub.2).sub.n -- linkage group where n is 1-8, and R is a -(CZ.sub.2).sub.n - linkage group where n is 6 or more and Z independently is H or a substituent such as a lower alkyl group, and the pharmaceutically acceptable salts of these compounds.

Growing community of inventors

Richmond, VA, United States of America

Billy R Martin